says Simon Ogden, Commercialization partner. “We are very selective on who we work with as there are so many companies claiming to have the best technology and we go through a rigorous exercise of differentiation.” Greffex is a prime example of that.
Early generation viral vectors can induce potent immune responses interfering with effectiveness of subsequent administration of the vector. The cause is incomplete deletion of endogenous proteins & traces of helper viruses used to manufacture the vector. The payload of earlier generation viral vectors is small limiting their use to (single dose) vaccines only.
2nd generation platforms addressed some of the limitations of the earlier generation by removing more genes, particularly those genes that result in pathogenesis. 3rd generation viral vectors went a stage further and removed all viral genes and relied on helper viruses for manufacturing.
However, the helper virus genetic materials is still incorporated and can cause unwanted immunogenicity.
Greffex has developed a patented 'Game Changer ' viral vector platform to deliver vaccines and gene therapies. Greffex's “GreGT fd Ad” is the first & best-in-class 4th gen vector platform that overcomes the drawbacks of older technologies by complete deletion of adenoviral genes and is manufactured without helper viruses.
Studies have shown that the platform is highly effective in animals. It is likely to provide long lasting protection and additional doses can be administered when needed with fewer adverse events than previous generations. For cell & gene therapy the 36Kb payload, a 4-fold increase over earlier generations, can accommodate the larger gene therapies that treat diseases that traditionally could not be treated.
The platform will deliver unprecedented time to market, cost efficiency, efficacy and safety through the use of proprietary clean adenoviral vectors.
The demand for assessing across modality technologies is significantly increasing and our operating model now has a specific niche for partnerships with technology companies
Greffex will shortly commence a phase I/II study that will investigate the safety, tolerability and immunogenicity of their platform in human subjects in preventing H5N1 Avian flu as a proof of principle study, as well as advancing gene therapies starting with Usher Syndrome and Cystic Fibrosis with NIH and private funds.
iWisdom is the commercialization partner, supporting Greffex with accelerating speed to market and financing for their first and best in class viral vector technology platform.
